Renaissance Technologies's NVO Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.9M shares of Novo Nordisk A/S (NVO) worth $159.92 M, representing 0.21% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in NVO, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 4.9M shares. Largest reduction occurred in Q2 2017, reducing 5.7M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +27.95 M | Add 0.00% | 27.95 M | $15.50 |
| Q3 2013 | +3.42 M | Add 12.22% | 31.36 M | $16.92 |
| Q4 2013 | +1.28 M | Add 4.07% | 32.64 M | $18.48 |
| Q1 2014 | -477,400 | Reduce 1.46% | 32.16 M | $22.83 |
| Q2 2014 | +1.75 M | Add 5.43% | 33.91 M | $23.09 |
| Q3 2014 | -1.69 M | Reduce 5.00% | 32.21 M | $23.81 |
| Q4 2014 | -983,000 | Reduce 3.05% | 31.23 M | $21.16 |
| Q1 2015 | -2.2 M | Reduce 7.05% | 29.03 M | $26.69 |
| Q2 2015 | -853,200 | Reduce 2.94% | 28.17 M | $27.38 |
| Q3 2015 | -1.83 M | Reduce 6.50% | 26.34 M | $27.12 |
| Q4 2015 | -544,400 | Reduce 2.07% | 25.8 M | $29.04 |
| Q1 2016 | -246,200 | Reduce 0.95% | 25.55 M | $27.09 |
| Q2 2016 | +348,200 | Add 1.36% | 25.9 M | $26.89 |
| Q3 2016 | +3.41 M | Add 13.16% | 29.31 M | $20.79 |
| Q4 2016 | -1.42 M | Reduce 4.83% | 27.89 M | $17.93 |
| Q1 2017 | +4.93 M | Add 17.66% | 32.82 M | $17.14 |
| Q2 2017 | -5.75 M | Reduce 17.52% | 27.07 M | $21.44 |
| Q3 2017 | +1.65 M | Add 6.11% | 28.72 M | $24.08 |
| Q4 2017 | +2.74 M | Add 9.54% | 31.46 M | $26.84 |
| Q1 2018 | +2.72 M | Add 8.65% | 34.18 M | $24.63 |
| Q2 2018 | +4.1 M | Add 12.00% | 38.28 M | $23.06 |
| Q3 2018 | +1.05 M | Add 2.74% | 39.33 M | $23.57 |
| Q4 2018 | +2.16 M | Add 5.48% | 41.49 M | $23.03 |
| Q1 2019 | +1.2 M | Add 2.89% | 42.69 M | $26.16 |
| Q2 2019 | +2.35 M | Add 5.51% | 45.04 M | $25.52 |
| Q3 2019 | +4.53 M | Add 10.06% | 49.57 M | $25.85 |
| Q4 2019 | +2.86 M | Add 5.77% | 52.43 M | $28.94 |
| Q1 2020 | +3.29 M | Add 6.27% | 55.72 M | $30.10 |
| Q2 2020 | +1.7 M | Add 3.05% | 57.42 M | $32.74 |
| Q3 2020 | -1.18 M | Reduce 2.05% | 56.24 M | $34.71 |
| Q4 2020 | -2.56 M | Reduce 4.55% | 53.68 M | $34.93 |
| Q1 2021 | -3.99 M | Reduce 7.43% | 49.69 M | $33.71 |
| Q2 2021 | -1.33 M | Reduce 2.68% | 48.36 M | $41.88 |
| Q3 2021 | -5.08 M | Reduce 10.51% | 43.28 M | $48.01 |
| Q4 2021 | -5.05 M | Reduce 11.66% | 38.23 M | $56.00 |
| Q1 2022 | -1.47 M | Reduce 3.83% | 36.77 M | $55.53 |
| Q2 2022 | -1.71 M | Reduce 4.65% | 35.06 M | $55.71 |
| Q3 2022 | -4.44 M | Reduce 12.67% | 30.62 M | $49.82 |
| Q4 2022 | -5.41 M | Reduce 17.67% | 25.21 M | $0.07 |
| Q1 2023 | -3.6 M | Reduce 14.30% | 21.6 M | $0.08 |
| Q2 2023 | -2.86 M | Reduce 13.25% | 18.74 M | $0.08 |
| Q3 2023 | -2.51 M | Reduce 13.41% | 16.23 M | $90.94 |
| Q4 2023 | -2.38 M | Reduce 14.67% | 13.85 M | $103.45 |
| Q1 2024 | -3.06 M | Reduce 22.12% | 10.79 M | $128.40 |
| Q2 2024 | -1.62 M | Reduce 15.03% | 9.17 M | $142.74 |
| Q3 2024 | -976,059 | Reduce 10.65% | 8.19 M | $119.07 |
| Q4 2024 | +123,681 | Add 1.51% | 8.31 M | $86.02 |
| Q1 2025 | -1.49 M | Reduce 17.94% | 6.82 M | $69.44 |
| Q2 2025 | -1.88 M | Reduce 27.63% | 4.94 M | $69.02 |
| Q3 2025 | -2.05 M | Reduce 41.62% | 2.88 M | $55.49 |
Renaissance Technologies's Novo Nordisk A/S Investment FAQs
Renaissance Technologies first purchased Novo Nordisk A/S (NVO) in Q2 2013, acquiring 27,946,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Novo Nordisk A/S (NVO) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Novo Nordisk A/S (NVO) was in Q2 2013, adding 27,946,000 shares worth $433.08 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,881,996 shares of Novo Nordisk A/S (NVO), valued at approximately $159.92 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.21% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Novo Nordisk A/S (NVO) was 57,419,662 shares, as reported at the end of Q2 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.